+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia



Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia



Molecular Neurobiology 54(1): 768-778



The endocannabinoid system (ECS) is a group of neuromodulatory lipids, enzymes, and receptors involved in numerous behavioral and physiological processes such as mood, memory, and appetite. Recently, longitudinal and postmortem studies have shown that the ECS might be involved in neuropsychiatric disorders like schizophrenia. However, despite the large amount of research, our knowledge of the ECS and its implication in this debilitating disorder is still largely limited. This review aims at providing a comprehensive overview of the current state of knowledge of the ECS in schizophrenia and presenting some potential antipsychotic compounds that modulate this system. Findings from animal and human studies, and their implications for pharmacotherapy, will be integrated and discussed in this paper. A closer look will be given at the roles of the cannabinoid receptors type 1 (CB1) and type 2 (CB2), as well as the endogenous ligand N-arachidonoylethanolamine (AEA) and 2-arachidonylglycerol (2-AG), in the development of psychotic and schizophrenia-like symptoms.

(PDF emailed within 0-6 h: $19.90)

Accession: 058791045

Download citation: RISBibTeXText

PMID: 26768595

DOI: 10.1007/s12035-016-9697-5


Related references

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention. Cns Drugs 32(7): 605-619, 2018

The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches. Journal of Clinical Psychiatry 75(3): 285-287, 2014

Role of endocannabinoid 2-arachidonoylglycerol in the physiology and pathophysiology of the cardiovascular system. Postepy Higieny i Medycyny Doswiadczalnej 68: 814-827, 2015

The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterology and Motility 20(8): 857-868, 2008

The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Revista Brasileira de Psiquiatria 34 Suppl 2: S163-S177, 2013

The Endocannabinoid System and its Role in Schizophrenia: A Systematic Review of the Literature. Revista Brasileira de Psiquiatria 34: 163-193, 2012

Dysregulation of endocannabinoid system in schizophrenia: the potential role of cannabinoid 1 receptor altered gene expression. European Neuropsychopharmacology 27: S10-S11, 2017

Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC). Progress in Neuro-Psychopharmacology and Biological Psychiatry 52: 53-69, 2014

The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy. Cns Drugs 2019, 2019

The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. Journal of Molecular Medicine 83(12): 944-954, 2005

Participation of endocannabinoid system in the pathophysiology of human placenta. Placenta 51: 109-110, 2017

Endocannabinoid system and energy metabolism: physiology and pathophysiology. Giornale Italiano di Cardiologia 9(4 Suppl 1): 74s-82s, 2008

Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. Diabetes & Metabolism 33(2): 97-107, 2007

Endocannabinoid system and pathophysiology of adipogenesis: current management of obesity. Personalized Medicine 4(3): 307-319, 2007

The endocannabinoid system and emotional processing: pathophysiology and therapeutic potential. Journal of Psychopharmacology 26(1): 3-6, 2012